Home > Healthcare > Pharmaceuticals > Finished Drug Form > Liver Metastases Treatment Market

Liver Metastases Treatment Market Size

  • Report ID: GMI9582
  • Published Date: May 2024
  • Report Format: PDF

Liver Metastases Treatment Market Size

Liver Metastases Treatment Market size was valued at USD 1.6 billion in 2023 and is anticipated to witness growth at a CAGR of 6.7% between 2024 and 2024. One of the primary drivers is the rising incidence of cancers such as colorectal, breast, and lung cancer, that often metastasize to the liver, has expanded the patient pool requiring treatment.

 

For instance, as per a study published in the National Institute of Health (NIH), liver is one of the most common sites for cancer metastasis, accounting for nearly 25% of all cases. Such high occurrence of liver metastasis increases the demand for treatments, thereby aiding in market growth. Moreover, increased awareness about early detection and treatment options among both patients and healthcare providers has led to more timely interventions, driving market growth. Furthermore, ongoing research and development efforts aimed at discovering novel therapies and targeted treatment modalities are expected to further propel the market growth.
 

Liver metastasis is the spread of cancer cells from a primary cancer site to the liver. Liver metastasis treatment include medical interventions aimed at managing cancer that has spread to the liver from another part of the body. The primary goal of treatment is typically to control the growth of cancer, alleviate symptoms, and prolong survival while maintaining a good quality of life for the patient.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Liver metastases treatment market size was valued at USD 1.6 billion in 2023 and is anticipated to grow at 6.7% CAGR during 2024-2032, driven by the rising incidence of cancers, such as colorectal, breast, and lung cancer.

The hospital pharmacies segment in the market is likely to record 6.4% CAGR between 2024-2032, as they offer a comprehensive range of specialized medications and therapies that are crucial for the effective management of liver metastases.

North America liver metastases treatment market size was valued at USD 680.3 million in 2023 and is anticipated to reach USD 1.2 billion by 2032, attributed to robust healthcare policies and insurance coverage.

AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Ono Pharmaceutical, and Pfizer, Inc.

Liver Metastases Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 202
  • Countries covered: 22
  • Pages: 114
 Download Free Sample